Delivery Order SPE2DB20D2014-SPE2DB25FC89J
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s on September 4, 2025, with a ceiling value of $1,616.16 and completion date of September 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under a larger contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a $1,725.36 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for 36,000 unit capsules of Creon DR 100s, with an ultimate completion date of August 8, 2025. The contract was competitively awarded with no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $3,088.91 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100 mg capsules. This non-competitive, firm fixed price delivery order was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a child contract under a larger vehicle, this delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $45,421.87 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s. This contract, executed on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed-price delivery order with no set-aside designation. The award was competitively procured and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Creon is a pancreatic enzyme replacement...
- The Defense Logistics Agency awarded a $109,239.08 firm fixed price delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s, with an ultimate completion date of August 4, 2025. This non-competitive delivery order, issued on August 1, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $42,783.63 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of 36,000 units of Creon DR 100s capsules. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by August 20, 2025. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of 36,000 units of Creon DR 100s capsules, valued at $6,150.38. This competitively awarded, firm fixed-price delivery order is set to be completed by July 30, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,004.53 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100 capsules, with an ultimate completion date of July 30, 2025. This contract represents a firm fixed price delivery order with no set-aside designation, awarded competitively on July 29, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Creon DR is an enzyme replacement therapy used to treat...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Creon DR 24,000 unit capsules (100 count) with a ceiling value of $2,262.52 and an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $10,850.92 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules on August 27, 2025, with an ultimate completion date of August 28, 2025. This non-set-aside, firm fixed-price delivery order represents a direct procurement of pharmaceutical supplies to support military and federal healthcare operations. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania,...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC89JDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 24,000 unit capsules of Creon DR 100s, with a ceiling value of $18,568.25. The contract, executed on September 3, 2025, with an ultimate completion date of September 4, 2025, utilizes firm fixed-price pricing under a non-competitive, non-set-aside delivery order. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same municipality. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. Creon DR is a pancreatic enzyme replacement therapy used to treat pancreatic insufficiency, representing the type of specialized pharmaceutical commodity essential to supporting Defense Health Agency operations and broader federal medical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.6k | 9/3/25 |